Humacyte (HUMA) Stock: Buy, Sell, or Hold?
HUMA - Humacyte, Inc. Common Stock
$0.44
0.02 (5.40%)
▲
5d:
+1.49%
30d:
-23.44%
90d:
-35.41%
BUY
HIGH Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 11, 2026
17d
Get Alerted When HUMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: HUMA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: HUMA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: HUMA is currently trading at $0.44, which is considered slightly low relative to its 30-day fair value range of $0.41 to $0.56.
Technical Outlook: Technically, HUMA is in a downtrend. Immediate support is located at $0.34, while resistance sits at $0.46. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: HUMA scores 84/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $1.62 (+273.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HUMA is in a downtrend. Immediate support is located at $0.34, while resistance sits at $0.46. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: HUMA scores 84/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $1.62 (+273.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.41 -
$0.56
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (84/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.4%)
- BULLISH: Trading 273.2% below Wall St target ($1.62)
- BULLISH: Bottoming setup score 84/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$0.41 -
$0.56
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.34
Resistance Level
$0.46
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.76
Wall Street Target
$1.63
(+273.2%)
Revenue Growth (YoY)
34.9%
Share & Embed Analysis
Last updated: October 23, 2026 10:16 PM ET
Data refreshes hourly during market hours. Next update: 11:16 PM
Data refreshes hourly during market hours. Next update: 11:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HUMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 73 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 69 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 43 HOLD |
|
RAPP
Rapport Therapeutics, In… |
STRONG BUY
16 analysts |
$63 | 54 HOLD |
